Fig. 2 | Hypertension Research

Fig. 2

From: Goreisan attenuates cardiac hypertrophy and diastolic dysfunction in heart failure with preserved ejection fraction induced by HFD/L-NAME via regulation of ICAT-β-catenin/ERK axis

Fig. 2

GRS ameliorated diastolic dysfunction and cardiomyocyte hypertrophy in HFpEF mice. A Representative echocardiographic images of mice fed normal diet, normal diet+GRS, HFD/L-NAME, or HFD/L-NAME + GRS for 5 weeks (n = 13–15). Long two-way arrows and short two-way arrows indicate left ventricular end-diastolic diameter (LVDd) and left ventricular end-systolic diameter (LVDs), respectively. B–D Quantitative analysis of LVDd, LVDs, LV ejection fraction (LVEF), and LV wall thickness evaluated by echocardiography at 5 weeks in the indicated groups (n = 13–15). E, F Representative echocardiographic images of LV inflow in the indicated groups. Quantitative analysis of ratios of E to A and E to e’ evaluated by echocardiography in the indicated groups (n = 13–15). G, H Representative images of wheat germ agglutinin (WGA)-stained heart sections in the indicated groups. Quantitative analysis of cardiomyocyte hypertrophy as assessed by cross-sectional area in the indicated groups (n = 6). Bar=20 μm. *P < 0.05, **P < 0.01: post-hoc Tukey’s comparison test

Back to article page